Compare Constellation Energy Corporation (CEG) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Constellation Energy Corporation vs Moderna, Inc. — how do they compare? Constellation Energy Corporation trades at $282.72 (market cap $98.63B), while Moderna, Inc. trades at $61.88 (market cap $24.18B). The key difference: Constellation Energy Corporation is far larger — about 4.1× Moderna, Inc.'s market cap, and Constellation Energy Corporation pays a 0.61% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| CEG | MRNA | |
|---|---|---|
Market Cap | $98.63B | $24.18B |
Sector | Energy | Health |
52-Week High | $403.95 | $81.80 |
52-Week Low | $236.50 | $22.36 |
Enterprise Value | $122.63B | $20.33B |
Dividend Yield | 0.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Constellation Energy (CEG) is trading at $281.84, up 4.22% today, with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with Q2 2026 EPS of $2.55 beating expectations by 11.4%, and raised 2026 guidance. Recent news highlights nuclear power contracts with major tech companies driving growth. Technical indicators show bullish momentum with support at $277 and resistance at $282.
CEG presents a compelling investment case with strong earnings momentum, AI-driven power demand tailwinds, and 70% analyst buy ratings. Risks include execution of nuclear capacity expansion and potential regulatory changes. The consensus price target of $332.13 suggests 18% upside potential from current levels.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Constellation Energy Corporation
Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.
Read more on CEG →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
